Interview with Eric Zwisler, President, Cardinal Health China
We last met with you as the head of Zuellig in 2009. Obviously, a lot has changed since then; from both a sector and corporate point of view, what have…
Yangtze River Pharmaceutical Group is a Chinese multinational pharmaceutical corporation headquartered in Taizhou, Jiangsu Province in the People’s Republic of China, and with its research headquarters in Shanghai. It is one of the Asia’s largest pharmaceutical companies by revenues, and was listed in 2014 as being China’s second largest pharmaceutical manufacturer, and leading company for technological and entrepreneurial innovation.
Founded in 1971, the Yangtze River Pharmaceutical Group started as a local firm providing drugstores and hospitals with vitamin supplements and pain medication. For much of its early existence, profit margins were low due to the YRPG’s inability to expand a fledgeling sales network past a local level. This changed at the end of the 20th century when sweeping economic and medical reforms placed an ever-increasing demand on quality drug production.[5] Located in a prime location between the major cities of Shanghai, Suzhou, and Hangzhou, the YRPG quickly expanded its business profile. The group has experienced significant growth in the past decade, having quadrupled their net income between 2003-2010.[1] In the fiscal year 2014, board shareholders received a record 560% return on investment, and company assets rapidly expanded.[1] The company also hosts 22 subsidiary firms across Asia and has exploratory ventures in Europe, Canada, and the United States.
We last met with you as the head of Zuellig in 2009. Obviously, a lot has changed since then; from both a sector and corporate point of view, what have…
Although MicroConstants traces its history back to 1998 in San Diego, you co-founded the China operations in 2007. What’s the story behind how that came about? It all began when…
Celgene is a relative newcomer to China. What’s the story behind how the company entered the market, and how did you yourself come to manage the local operations? I officially…
Among Big Pharma, Sanofi has a track record of placing a lot of faith in emerging markets – with local production, a large product portfolio, and decades of experience. As…
One of the earliest innovative biotech companies in China, Zensun has developed what its founder Dr. Zhou Mingdong calls a rare made-in-China first-in-class therapeutic candidate, Neucardin®, which has been shown…
From out meeting with BPBC in 2009, we know that your slogan is to “grow up with industry.” How have you grown up since then? Firstly, I’d like to reiterate…
Chen Qiyu, chairman of Fosun Pharma, discusses how the company is helping China achieve its ‘Healthy China 2020’ goals as well as its unique business model and company culture. Fosun…
This is our first meeting in Shanghai after being based in Beijing for two months – what if any are the differences between the two cities? At the top level,…
Hu Jintao recently announced his ambitions for China to be “an innovative country” by 2020? Could you speak to the likelihood of achieving this in terms of biotechnology as you…
You spent two decades in the US as an academic, executive, and entrepreneur, and then left to return to China and found AbMax. What’s the story behind how you came…
It seems like there’s a lot to be happy about here: Pfizer is ranked number 1 multinational R&D-based biopharmaceutical company in China, where you also have two world-class R&D centers…
The Chamber recently released this year’s European Business in China Business Confidence Survey – what were some of its key takeaways? There are four main points to the Survey. The…
See our Cookie Privacy Policy Here
